Biosimilar Code Blending By CMS Could Cause Tracking, Payment Problems
This article was originally published in The Pink Sheet Daily
Executive Summary
Rivals Sandoz and Amgen both say CMS decision on J-codes removes feature for tracking adverse events.
You may also be interested in...
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
US FDA’s Standard Application Assessment Makes A Comeback
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.
Gene Therapy: Nonclinical Questions Do Not Seem Ideal For The US FDA’s New Type D Meeting
Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.